Pathlab sector stocks have been underperforming for the last few weeks after excessively gaining returns since the beginning of the year. Dr Lal Pathlabs gained 52% from the beginning of the year and since November the stock has lost 3.6% value. Same goes with Metropolis Healthcare and Thyrocare Pathlabs. Keshav Lahoti from Angel Broking accertains, this downward trend is a result of government reducing COVID-19 RT PCR tests recently, while the contrary happened in the beginning of the year when pathlabs earned additional revenue from these testings.
Explained: Why pathlabs are losing stock value from few weeks
